Silence Therapeutics plc (NASDAQ:SLN – Get Rating) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 26,700 shares, a growth of 24.2% from the October 31st total of 21,500 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 42,400 shares, the short-interest ratio is presently 0.6 days.
Institutional Trading of Silence Therapeutics
Several institutional investors have recently added to or reduced their stakes in SLN. TCG Crossover Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth $21,122,000. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of Silence Therapeutics in the first quarter worth $29,669,000. BVF Inc. IL grew its stake in shares of Silence Therapeutics by 126.3% in the third quarter. BVF Inc. IL now owns 1,508,416 shares of the company's stock worth $14,888,000 after acquiring an additional 841,750 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Silence Therapeutics by 27.1% in the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock worth $18,350,000 after acquiring an additional 205,815 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Silence Therapeutics in the first quarter worth $16,742,000. Institutional investors and hedge funds own 72.14% of the company's stock.
Get Silence Therapeutics alerts:Silence Therapeutics Price Performance
Shares of SLN stock traded up $0.56 during trading on Thursday, hitting $16.24. 44,029 shares of the stock traded hands, compared to its average volume of 36,002. Silence Therapeutics has a 52-week low of $7.80 and a 52-week high of $26.84. The firm's fifty day moving average price is $11.87 and its 200-day moving average price is $10.84. The firm has a market capitalization of $582.82 million, a P/E ratio of -10.51 and a beta of 0.82.
Analyst Ratings Changes
Separately, Chardan Capital dropped their target price on Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating on the stock in a research report on Thursday, November 17th.About Silence Therapeutics
(Get Rating)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Stories
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is The Recovery Rally Here For SoFi?
- Is Apple Going To Rally Into Year End?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.